Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BMS-986202 in Healthy Subjects and Psoriasis
NCT02763969Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986202 in plaque psoriasis (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety of a single oral dose of BMS-986202 at 4 weeks, Safety of a multiple oral dose of BMS-986202 at 4 weeks and 2 more. Started May 2016; status: completed.
02
Drugs
BMS-986202
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02763969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763969.